Loading…
← CockpitCompetitor Analysis › AGIO Agios Pharmaceuticals, Inc.Open in the cockpit ↗

Agios Pharmaceuticals, Inc.AGIOCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Rare-disease biotech selling Pyrukynd for pyruvate kinase deficiency, expanding into sickle cell and thalassemia.

Momentum weak 39
Mkt cap
$1.78B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$35.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-96.4 pp
WACC 8.3%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$29.68
1D-0.7%
1W-9.6%
1M-19.0%
3M-11.8%
6M+4.1%
YTD+9.0%
1Y-34.2%
ATR %5.9%
Beta1.03
52w lowhigh35.5% off high

What Agios Pharmaceuticals does

Rare-disease biotech selling Pyrukynd for pyruvate kinase deficiency, expanding into sickle cell and thalassemia.

Since selling its cancer drugs to Servier in 2021, it has been a rare-blood-disease company, selling Pyrukynd in the US to a small number of patients. Value depends on whether the same drug wins approval in broader blood disorders.

Products and services

  • Pyrukynd (PK deficiency)
  • Pyrukynd (thalassemia, expanding)
  • Sickle cell pipeline

Customers

  • Hematologists

Where it sits in the supply chain

  • Rare hematology biopharma
  • Pyruvate kinase activator drug…
  • Specialty hematology commercialization

What could go right

  • Thalassemia/sickle cell label expansion
  • International launch expansion

What could go wrong

  • Small addressable patient populations
  • Reimbursement pressure on rare-disease pricing

Moat: narrow (IP / patents, regulatory licence). First-in-class pyruvate kinase activator with orphan-drug exclusivity in a rare-disease niche.

Headquarters: Cambridge, Massachusetts, US · Founded: 2007 · Employees: 540

Named competitors

Agios Pharmaceuticals at a glance

Size Agios Pharmaceuticals (AGIO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.78B, the 1854th largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.68 on 18 Nov 2026.

Performance Over six months the shares gained 4.1%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 214.4% over the last twelve months (peer median +4.2%); the operating margin is -297.7% (peer median 10.0%).

Valuation It trades at 8.3× enterprise value to sales against a peer median of 3.6× (7th most expensive of 21).

Capital Return on invested capital runs 96.4 points below its cost of capital (8.3% WACC).

Short interest Short interest is 10.9% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026AGIO 103Peer median 97
Six months, rebased to 100: Agios Pharmaceuticals against the median of its 20 peers (local-currency closes).

Agios Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$141M$54.0M$36.5M$26.8M$14.2M
Revenue growth—+48%+36%+88%—
Gross profit$127M$42.5M$26.7M$17.3M-$6.02M
EBITDA-$414M-$467M-$420M-$385M-$370M
Net income-$373M-$413M$674M-$352M-$232M
Free cash flow-$336M-$377M-$392M-$297M-$314M
Capital expenditure$4.28M$4.32M$1.69M$999,000$4.88M
Total debt$26.5M$40.2M$57.0M$72.0M$85.7M

Quarterly statements and history in the cockpit →

Agios Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%+10%9989600664ETON3933301015RAREZYME000028605507NATCOPHARM300573688166MAZEFAEDMP300723000908CAPLIPOINTINDGNAGIO6-month return →1-month return →
Up and to the right = strong over both horizons. Agios Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×10×20×9989600664ETON3933RAREZYMENATCOPHARM688166MAZEFAE300723000908CAPLIPOINTINDGNAGIORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Agios Pharmaceuticals is the large dot.

Agios Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (AGIO vs NOVN.SW vs BMY vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Agios Pharmaceuticals AGIO$1.78B+4%+214%-298%8.3×n/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%
Vertex Pharmaceuticals VRTX$136B+25%+11%35%10.5×6.2%
Beam Therapeutics BEAM$2.17B-22%+163%-268%9.4×n/a

How Agios Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Agios Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureAGIOPeer medianRank in peer set
1-month return-19.0%+0.5%lowest of 21
6-month return+4.1%-4.7%7th highest of 21
Distance from 52-week high-35.5%-32.1%9th lowest of 21
Revenue growth (TTM)+214.4%+4.2%highest of 21
Operating margin-297.7%10.0%2nd lowest of 21
EV / Sales8.3×3.6×7th most expensive of 21
ROIC minus cost of capital-96.4 pp+1.2 pp2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%8.3×n/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%2.1×-0.4%-0.2%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%0.7×-5.3%+8.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%12.4×21.9%+359.6%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%0.6×1.2%+7.8%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%2.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%3.7×n/an/a
Zymeworks ZYMEUnited States$1.81B+5%+98%17%8.9×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%0.3×-9.5%+4.2%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%1.9×-6.0%+7.4%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%5.1×20.5%+19.0%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%4.2×5.4%+29.1%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%9.7×35.3%+9.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%68.8×n/an/a
Faes Farma FAE.MCSpain$1.71B+6%+32%14%2.6×3.7%+9.9%
Dermapharm DMP.DEGermany$1.85B-29%+2%21%2.3×-3.4%+8.0%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%16.7×11.3%-11.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%25.8×n/an/a
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%6.3×24.3%+15.7%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%2.3×-3.5%+6.8%
Indegene INDGN.NSIndia$1.69B+28%+36%12%3.6×31.4%+29.4%

Questions

Who are Agios Pharmaceuticals's main competitors?
Named competitors: Novartis (NOVN.SW), Bristol Myers Squibb (BMY), Pfizer (Global Blood Therapeutics) (PFE), Novo Nordisk (NOVO-B.CO), Vertex Pharmaceuticals (VRTX), Fulcrum Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes Shenzhen Hepalink Pharmaceutical (9989.HK), Harbin Pharmaceutical (600664.SS), Eton Pharmaceuticals (ETON), United Laboratories International (3933.HK), Qingdao Baheal Medical (301015.SZ), Ultragenyx Pharmaceutical (RARE).
Is Agios Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 8.3× against a peer median of 3.6×, 7th most expensive of 21 in its peer set.
How has Agios Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +4.1% against -4.7% for the median peer; over one year -34.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.